Michelle Gau
About Michelle Gau
Michelle Gau is a Senior Immuno Oncology Representative at Bristol-Myers Squibb in Edmond, Oklahoma, with a background in oncology and ophthalmology sales and a strong academic foundation in communications.
Current Title at Bristol-Myers Squibb
Michelle Gau serves as a Senior Immuno Oncology Representative at Bristol-Myers Squibb, based in Edmond, Oklahoma. In this role, she is responsible for promoting immuno-oncology products, such as Opdivo and Yervoy. Her work focuses on educating healthcare professionals and aiding in the development of treatment protocols utilizing these innovative therapies.
Previous Experience at Boehringer Ingelheim
From 2013 to 2015, Michelle Gau worked as an Oncology Consultant for Boehringer Ingelheim, covering the Oklahoma and Kansas regions. During her tenure, she was pivotal in promoting cancer treatment therapies and facilitating their adoption within the medical community. Her efforts contributed significantly to the company’s oncology sales performance.
Clinical Oncology Specialist at Genentech
Between 2007 and 2011, Michelle Gau served as a Clinical Oncology Specialist at Genentech. In this role, she was involved in presenting clinical data and therapeutic options to oncologists and healthcare providers in Oklahoma and Kansas. Her contributions were crucial in expanding the reach and impact of Genentech’s oncology portfolio.
Educational Background and Expertise
Michelle Gau holds an MA in Speech Communication and Consulting from Oklahoma State University, earned between 1994 and 1996. She also has a BA in Oral Communications/Public Relations from the University of Central Oklahoma, completed from 1990 to 1994. Her foundational education was completed at Shawnee High School, where she obtained her diploma in 1990. This diverse educational background has equipped her with strong communication skills and a sophisticated understanding of public relations.
Professional Achievements in Oncology Sales
Throughout her career, Michelle Gau has achieved significant milestones. She secured the top ranking (1/88) in January 2023 for selling Opdivo and Yervoy. Additionally, she was ranked 4th out of 80 in 2014 for selling Gilotrif, a targeted therapy for metastatic non-small cell lung cancer, and achieved the top ranking (1/40) in the West Zone for selling Gilotrif in the same year. Her leadership roles include National Compliance Lead in 2014 and National Advisory Board Member in 2015.